National Institute on Aging; Notice of Closed Meeting, 39001 [2019-16955]

Download as PDF 39001 Federal Register / Vol. 84, No. 153 / Thursday, August 8, 2019 / Notices Dated: August 2, 2019. Sylvia L. Neal, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2019–16923 Filed 8–7–19; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Aging; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. jbell on DSK3GLQ082PROD with NOTICES Name of Committee: National Institute on Aging Special Emphasis Panel; T32 and T35 Review, January 2020 Council ZAG1 ZIJ–U (J4). Date: October 18, 2019. Time: 8:00 a.m. to 6:30 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Anita H. Undale, MD, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute on Aging, National Institutes of Health, Gateway Building, Suite 2W200, 7201 Wisconsin Avenue, Bethesda, MD 20892, 301–827– 7428, anita.undale@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS) Dated: August 2, 2019. Sylvia L. Neal, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2019–16955 Filed 8–7–19; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive Patent License: Lutetium-177 Radiotherapeutics Against Glioblastoma Multiforme and SmallCell Lung Carcinoma AGENCY: National Institutes of Health, HHS. ACTION: Notice. NIH Ref No. Patent No. or patent application No. Filing date E–150–2016–0–US–01 ............. 62/333,427 .................. May 9, 2016 ............... E–150–2016–0–PCT–02 ........... PCT/US2017/031696 May 9, 2017 ............... E–150–2016–0–CN–03 ............. 201780029003X ......... November 9, 2018 ...... E–150–2016–0–EP–04 .............. 17796666.0 ................. November 12, 2018 .... E–150–2016–0–JP–05 .............. 2018–558662 .............. November 8, 2018 ...... E–150–2016–0–US–06 ............. 16/099,488 .................. November 7, 2018 ...... E–150–2016–0–SG–07 ............. 11201809982R ........... November 9, 2018 ...... E–150–2016–1–PCT–01 ........... PCT/US2017/054863 October 3, 2017 ......... The patent rights in these inventions have been assigned to the Government of the United States of America. The prospective patent license will be granted worldwide and in a field of use not broader than Lutetium-177 radiotherapeutics containing RGDpeptide moieties targeting integrin avb3-expressing glioblastoma multiforme and small cell lung cancers. The invention pertains to a radiotherapeutic against cancers that overexpress integrin avb3. RGD peptide- VerDate Sep<11>2014 16:51 Aug 07, 2019 Jkt 247001 Frm 00075 Fmt 4703 Only written comments and/or applications for a license which are received by the NHLBI Office of Technology Transfer and Development August 23, 2019 will be considered. DATES: Requests for copies of the patent applications, inquiries, and comments relating to the contemplated exclusive patent license should be directed to: Michael Shmilovich, Esq., Senior Licensing and Patent Manager, 31 Center Drive, Room 4A29, MSC2479, Bethesda, MD 20892–2479, phone number 301–435–5019, or shmilovm@ mail.nih.gov. ADDRESSES: The following and all continuing U.S. and foreign patents/patent applications thereof are the intellectual properties to be licensed under the prospective agreement to MTTI: SUPPLEMENTARY INFORMATION: Title Chemical Conjugates of Evans Blue Derivatives and and Imaging Agents. Chemical Conjugates of Evans Blue Derivatives and and Imaging Agents. Chemical Conjugates of Evans Blue Derivatives and and Imaging Agents. Chemical Conjugates of Evans Blue Derivatives and and Imaging Agents. Chemical Conjugates of Evans Blue Derivatives and and Imaging Agents. Chemical Conjugates of Evans Blue Derivatives and and Imaging Agents. Chemical Conjugates of Evans Blue Derivatives and and Imaging Agents. Chemical Conjugates of Evans Blue Derivatives And And Imaging Agents. targeted radionuclide therapy directed against tumors that express integrin avb3 has proven effective for the treatment of advanced, low- to intermediate-grade tumors. The subject radiotherapeutic covered by the patent estate includes an RGD peptide (arginylglycylaspartic acid [Arg-GlyAsp], linear or cyclical), conjugated to an Evans Blue (EB) analog, and further chelated via DOTA to therapeutic radionuclide 177Lu, a beta emitter. The EB analog reversibly binds to circulating PO 00000 The National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to Molecular Targeting Technologies, Inc. (MTTI); a Delaware corporation, with its principle place of business in West Chester, Pennsylvania, to practice the inventions embodied in the patent application listed in the Supplementary Information section of this notice. SUMMARY: Sfmt 4703 Their Use as Radiotherapy Their Use as Radiotherapy Their Use as Radiotherapy Their Use as Radiotherapy Their Use as Radiotherapy Their Use as Radiotherapy Their Use as Radiotherapy Their Use As Radiotherapy serum albumin and improves the pharmacokinetics of RGD peptide DOTA conjugated radiotherapeutics and potentially toxicity. The EB analog conjugated has been shown by the inventors to provide reversible albumin binding in vivo and extended half-life in circulation. This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive patent license will be royalty bearing and may be granted unless within fifteen (15) days from the date of this E:\FR\FM\08AUN1.SGM 08AUN1

Agencies

[Federal Register Volume 84, Number 153 (Thursday, August 8, 2019)]
[Notices]
[Page 39001]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-16955]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Aging; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Aging Special Emphasis 
Panel; T32 and T35 Review, January 2020 Council ZAG1 ZIJ-U (J4).
    Date: October 18, 2019.
    Time: 8:00 a.m. to 6:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 
Wisconsin Avenue, Bethesda, MD 20814.
    Contact Person: Anita H. Undale, MD, Ph.D., Scientific Review 
Officer, Scientific Review Branch, National Institute on Aging, 
National Institutes of Health, Gateway Building, Suite 2W200, 7201 
Wisconsin Avenue, Bethesda, MD 20892, 301-827-7428, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging 
Research, National Institutes of Health, HHS)

    Dated: August 2, 2019.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-16955 Filed 8-7-19; 8:45 am]
 BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.